Please login to the form below

Not currently logged in
Email:
Password:

Jounce

This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.

Celgene cuts back Jounce alliance ahead of BMS merger

Celgene cuts back Jounce alliance ahead of BMS merger

Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics